BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 34524695)

  • 1. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test.
    Kitagawa Y; Imai K; Matsuoka M; Fukada A; Kubota K; Sato M; Takada T; Noguchi S; Tarumoto N; Maesaki S; Takeuchi S; Maeda T
    J Med Virol; 2022 Jan; 94(1):335-341. PubMed ID: 34524695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre-pandemic controls.
    Jung K; Shin S; Nam M; Hong YJ; Roh EY; Park KU; Song EY
    J Clin Lab Anal; 2021 Sep; 35(9):e23921. PubMed ID: 34369009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott).
    Charpentier C; Ichou H; Damond F; Bouvet E; Chaix ML; Ferré V; Delaugerre C; Mahjoub N; Larrouy L; Le Hingrat Q; Visseaux B; Mackiewicz V; Descamps D; Fidouh-Houhou N
    J Clin Virol; 2020 Nov; 132():104618. PubMed ID: 32919222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
    Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
    Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study.
    Al-Mughales JA; Al-Mughales TJ; Saadah OI
    Front Immunol; 2021; 12():705441. PubMed ID: 34539635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.
    Peterhoff D; Glück V; Vogel M; Schuster P; Schütz A; Neubert P; Albert V; Frisch S; Kiessling M; Pervan P; Werner M; Ritter N; Babl L; Deichner M; Hanses F; Lubnow M; Müller T; Lunz D; Hitzenbichler F; Audebert F; Hähnel V; Offner R; Müller M; Schmid S; Burkhardt R; Glück T; Koller M; Niller HH; Graf B; Salzberger B; Wenzel JJ; Jantsch J; Gessner A; Schmidt B; Wagner R
    Infection; 2021 Feb; 49(1):75-82. PubMed ID: 32827125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical diagnostic performance evaluation of five immunoassays for antibodies to SARS-CoV-2 diagnosis in a real-life routine care setting.
    Akyala AI; Awayimbo JR; Ogo AC; Chima NJ; Billyrose OMA; Engom AOG
    Pan Afr Med J; 2021; 39():3. PubMed ID: 34178231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of commercially available fully automated and ELISA-based assays for detecting anti-SARS-CoV-2 neutralizing antibodies.
    Zedan HT; Yassine HM; Al-Sadeq DW; Liu N; Qotba H; Nicolai E; Pieri M; Bernardini S; Abu-Raddad LJ; Nasrallah GK
    Sci Rep; 2022 Nov; 12(1):19020. PubMed ID: 36347859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can commercial automated immunoassays be utilized to predict neutralizing antibodies after SARS-CoV-2 infection? A comparative study between three different assays.
    Ismail A; Shurrab FM; Al-Jighefee HT; Al-Sadeq DW; Qotba H; Al-Shaar IA; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Front Biosci (Landmark Ed); 2021 Jul; 26(7):198-206. PubMed ID: 34340267
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
    Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
    Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, performance evaluation, and clinical application of a Rapid SARS-CoV-2 IgM and IgG Test Kit based on automated fluorescence immunoassay.
    Kang K; Huang L; Ouyang C; Du J; Yang B; Chi Y; He S; Ying L; Chen G; Wang J
    J Med Virol; 2021 May; 93(5):2838-2847. PubMed ID: 33231312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
    Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S; Rostad CA; Tompkins SM; Anderson EJ; Anderson LJ
    Microbiol Spectr; 2021 Oct; 9(2):e0045821. PubMed ID: 34494855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand.
    Putcharoen O; Wacharapluesadee S; Chia WN; Paitoonpong L; Tan CW; Suwanpimolkul G; Jantarabenjakul W; Ruchisrisarod C; Wanthong P; Sophonphan J; Chariyavilaskul P; Wang LF; Hemachudha T
    PLoS One; 2021; 16(2):e0246864. PubMed ID: 33577615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
    Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of Neutralizing Antibody Responses Following Natural SARS-CoV-2 Infection and Correlation with Commercial Serologic Tests. A Reappraisal and Indirect Comparison with Vaccinated Subjects.
    Gillot C; Favresse J; Maloteau V; Dogné JM; Douxfils J
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.
    Jalkanen P; Pasternack A; Maljanen S; Melén K; Kolehmainen P; Huttunen M; Lundberg R; Tripathi L; Khan H; Ritvos MA; Naves R; Haveri A; Österlund P; Kuivanen S; Jääskeläinen AJ; Kurkela S; Lappalainen M; Rantasärkkä K; Vuorinen T; Hytönen J; Waris M; Tauriainen S; Ritvos O; Kakkola L; Julkunen I
    J Infect Dis; 2021 Jul; 224(2):218-228. PubMed ID: 33905505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration.
    Simon G; Favresse J; Gillot C; Closset M; Catry É; Dogné JM; Douxfils J; Wieërs G; Bayart JL
    Clin Chem Lab Med; 2023 Sep; 61(10):1875-1885. PubMed ID: 37078220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
    Bošnjak B; Stein SC; Willenzon S; Cordes AK; Puppe W; Bernhardt G; Ravens I; Ritter C; Schultze-Florey CR; Gödecke N; Martens J; Kleine-Weber H; Hoffmann M; Cossmann A; Yilmaz M; Pink I; Hoeper MM; Behrens GMN; Pöhlmann S; Blasczyk R; Schulz TF; Förster R
    Cell Mol Immunol; 2021 Apr; 18(4):936-944. PubMed ID: 33139905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.